Biotech Values

[Fress]

SURF Oncology Chart speaks for itself.

https://stockcharts.com/h-sc/ui?s=SURF

About Surface Oncology®
SURF team is on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families.

Cathie Wood ARKG owns 10% of the total shares.
Novartis owns 10% of the total shares.
Eli Lily holds 8.5% through LLV ventures fund.
institutions own 67% of the 40 million shares outstanding

Potential of 1.2 Billion in total payments from Novartis & GSK with double digit royalties. Also partnered with Merck.

https://www.fiercebiotech.com/biotech/gsk-puts-up-to-815m-table-for-surface-oncology-s-antibody

Surface Oncology (SURF) Explores Potential Sale After GSK Takeover Approach - Source
https://www.streetinsider.com/Hot+M+and+A/Surface+Oncology+%28SURF%29+Explores+Potential+Sale+After+GSK+Takeover+Approach+-+Source/17458243.html

http://www.surfaceoncology.com

$SURF